Gastrointestinal Drugs Market Forecast by 2031
Introduction The factors driving the gastrointestinal drugs market include the growing cases of chronic constipation among all age groups, a surge in sales of over-the-counter remedies, a growing need for laxatives, and increasing product offerings from manufacturers. Pharmaceutical companies are investing in research and development aimed at creating new and more effective gastrointestinal medications. Rising investments in the development of biologics and the introduction of biosimilars are fueling the expansion of the market for gastrointestinal drugs.
BY DRUG CLASS
SEGMENTS COVERED
Biologics Antidiarrheal and Laxatives Acid Neutralizers Anti-inflammatory Drugs Antiemetic and Antinauseants
BY ROUTE OF ADMINISTRATION Oral and Parenteral
BY APPLICATION Irritable Bowel Syndrome Inflammatory Ulcerative Colitis Crohns Disease Gastroenteritis Celiac Disease
MARKET SIZE In 2023 - US$ 59,713.68 Million by 2031 - US$ 106,304.81 Million CAGR (2023 - 2031): 7.5%
Company Profile Sanofi SA GSK Plc Johnson & Johnson Bausch Health Companies Inc AstraZeneca Pl, Takeda Pharmaceutical Co Ltd AbbVie Inc Bayer AG Pfizer Inc Celltrion Inc.
Regional Analysis NORTH AMERICA EUROPE ASIA-PACIFIC SOUTH AND CENTRAL AMERICA MIDDLE EAST AND AFRICA
KEY BENEFITS Save and reduce time carrying out entrylevel research by identifying the growth, size, leading players, and segments in the global cryogenic control valve market.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
CONTACT US UNITED STATES : +1-646-491-9876 www.theinsightpartners.com
[email protected]
